Haemodynamic and electrocardiographic consequences of severe nicorandil toxicity

Emergency Medicine Journal

Volumn 20, Issue 1, 2003, Pages 98-100

  Greenwood, John P ^a   Malik, I ^b   Jennings, P ^c   Stevenson, R N ^c  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^c HUDDERSFIELD ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; DOPAMINE; INOTROPIC AGENT; NICORANDIL; NORADRENALIN;

ADULT; ARTERIAL PRESSURE; ARTICLE; CASE REPORT; CENTRAL VENOUS PRESSURE; CLINICAL FEATURE; CORONARY ARTERY BLOOD FLOW; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG OVERDOSE; ELECTROCARDIOGRAPHY; EMERGENCY WARD; EXERCISE TEST; FEMALE; FLUID THERAPY; HEADACHE; HEART ARRHYTHMIA; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VOLUME; HEMODYNAMIC MONITORING; HEMODYNAMICS; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; INGESTION; PRIORITY JOURNAL; SHOCK; ST SEGMENT DEPRESSION; SYMPTOM; T WAVE; TABLET; THORAX PAIN; VASODILATATION; VOMITING;

EID: 0037260972     PISSN: 13510622     EISSN: None     Source Type: Journal    
DOI: 10.1136/emj.20.1.98     Document Type: Article

References (10)

1. The IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: The impact of nicorandil in angina (IONA) randomised trial. Lancet 2002;359:1269-75.
2. Akai K, Wang Y, Sato K, et al. Vasodilatory effect of nicorandil on coronary arterial microvessels: Its dependency on vessel size and the involvement of the ATP-sensitive potassium channels. J Cardiovasc Pharmacol 1995;26:541-7.
3. Purcell H, Patel D, Mulcahy D, Fox KM, et al. In: Messerli FH, ed. Cardiovascular Drug Therapy. Philadelphia: WB Saunders, 1996:1638-45.
4. Krumenacker M, Roland EO. Clinical profile of nicorandil: An overview of its haemodynamic properties and therapeutic efficacy. J Cardiovasc Pharmacol 1992;20:S93-102.
5. Frampton J, Buckley M, Fitton A. Nicorandil: A review of its pharmacology and therapeutic efficacy in angina pectoris. Drugs 1992;44:625-55.
6. Ito H, Taniyama Y, Iwakura K, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 1999;33:654-60.
7. Patel DJ, Purcell HJ, Fox KM. Cardioprotection by opening of the K(ATP) channel in unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomised study with nicorandil. (CESAR 2 investigation: Clinical European studies in angina and revascularisation). Eur Heart J 1999;20:51-7.
8. Dunn N, Freemantle S, Pearce G, et al. Safety profile of nicorandil - Prescription-event monitoring (PEM) study. Pharmacoepidemiology and Drug Safety 1999;8:197-205.
9. Watanabe O, Okumura T, Takeda H, et al. Nicorandil, a potassium channel opener, abolished torsades de pointes in a patient with complete atrioventricular block. Pacing Clin Electrophysiol 1999;22:686-8.
10. Kobayashi Y, Miyata A, Tanno K, et al. Effects of nicorandil, a potassium channel opener, on idiopathic ventricular tachycardia. J Am Coll Cardiol 1998;32:1377-83.